TANTIGEN 2.0

TANTIGEN 2.0 catalogs tumor T cell antigens, epitopes, neoantigens, HLA ligands and validated TCR sequences to support analysis of antigen presentation and T cell recognition in cancer.

Key Features:

• Database content: Contains 4,296 antigen variants derived from 403 unique tumor antigens.
• T cell epitopes and HLA ligands: Includes more than 1,500 T cell epitopes and HLA ligands.
• Neoantigens: Incorporates neoantigens defined as tumor-specific antigens arising from mutations that generate novel amino acid sequences within tumor proteins.
• Validated TCR sequences: Integrates validated T-cell receptor (TCR) sequences specific to cognate T cell epitopes.
• Expression data: Includes gene, mRNA, and protein expression data for tumor antigens across major human cancers sourced from the Human Pathology Atlas.
• Integrated analytics: Provides tailored data analytics tools integrated with the dataset to support analysis workflows.

Scientific Applications:

• Immunotherapy target identification: Identification of potential targets for cancer immunotherapy based on antigen and epitope data.
• Immune evasion studies: Study of immune evasion mechanisms in tumors using antigen, neoantigen, and expression data.
• Personalized vaccine development: Support for the development of personalized cancer vaccines by cataloging neoepitopes and cognate TCRs.
• Antigen presentation and recognition analysis: Analysis of antigen presentation and T cell recognition using integrated epitope, HLA ligand, and TCR information.

Methodology:

Integration of antigen variants, T cell epitopes, HLA ligands, neoantigens and validated TCR sequences, incorporation of gene/mRNA/protein expression data from the Human Pathology Atlas, and integration of tailored data analytics tools.